Soft gelatin capsule formulation
US10774091B2 · kind B2 · utility
3Cited by
2References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 13, 2019 |
| Grant date | Sep 15, 2020 |
| Priority date | — |
| Expiry date | Mar 13, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.